Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
Heba Youssef, Clinical Nutrition Pharmacist at Helwan General Hospital, shared a post on LinkedIn:
“Heparin-Induced Thrombocytopenia (HIT): The Prothrombotic Emergency You Cannot Miss
Heparin saves lives in the ICU – but in some patients, it silently triggers a life-threatening clotting cascade. Missing HIT is not an option.
What Is HIT?
IgG antibodies form against PF4-heparin complexes, causing:
- Platelet activation and consumption
- Massive thrombin generation
- High risk of arterial AND venous thrombosis
Critical reminder: HIT is a PROTHROMBOTIC disorder – not a bleeding disorder.
When to Suspect HIT?
- Platelet fall greater than or equals to 50% from baseline within 5-10 days of heparin exposure
- New thrombosis, skin necrosis at injection sites, or acute systemic reaction after IV heparin bolus
Pearl: A normal platelet count does NOT exclude HIT if it has fallen greater than or equal to 50% from baseline.
Calculate the 4Ts Score First
- 0–3 equals Low probability
- 4–5 equals Intermediate probability
- 6–8 equals High probability
Score greater than or equal to 4? Stop ALL heparin immediately. Do NOT wait for lab confirmation.
Diagnostic Steps
- 4Ts Score
- PF4-Heparin Immunoassay (ELISA)
- Serotonin Release Assay (SRA) – Gold Standard
Management
Stop ALL heparin sources – UFH, LMWH, flushes, heparin-coated devices.
Start a Non-Heparin Anticoagulant:
- Critically ill: Argatroban or Bivalirudin
- Clinically stable: DOACs or Fondaparinux
DOACs in acute HIT: not yet universally approved – follow institutional protocols.
Never give Warfarin in acute HIT.
Avoid platelet transfusion unless life-threatening bleeding.
Duration of Therapy
- Isolated HIT: Until platelet recovery (approximately 4 weeks)
- HIT with Thrombosis: 3-6 months
Never Forget
- Platelet fall greater than or equal to50% matters more than the absolute count
- Untreated HIT – thrombosis in 30–50% of patients
- Always rule out: sepsis, DIC, CRRT, ECMO, drug-induced thrombocytopenia
- Never delay treatment while awaiting confirmatory testing”

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian